These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14718592)

  • 1. Emerging pharmacologic approaches for the treatment of lower urinary tract disorders.
    Moreland RB; Brioni JD; Sullivan JP
    J Pharmacol Exp Ther; 2004 Mar; 308(3):797-804. PubMed ID: 14718592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erectile dysfunction and lower urinary tract.
    Sandner P; Neuser D; Bischoff E
    Handb Exp Pharmacol; 2009; (191):507-31. PubMed ID: 19089343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.
    Uckert S; Stief CG
    Handb Exp Pharmacol; 2011; (204):307-22. PubMed ID: 21695646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia.
    Rosen RC
    Curr Opin Urol; 2006 Jan; 16(1):11-9. PubMed ID: 16385195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence.
    Andersson KE; Wein AJ
    Pharmacol Rev; 2004 Dec; 56(4):581-631. PubMed ID: 15602011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
    Gales BJ; Gales MA
    Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enlarging the scope of managing benign prostatic hyperplasia: addressing sexual function and quality of life.
    Martin DJ; Mulhall JP
    Int J Clin Pract; 2005 May; 59(5):579-90. PubMed ID: 15857355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.
    Pimentel H; Wald M; Niederberger C
    Int J Impot Res; 2008; 20(2):145-9. PubMed ID: 18075506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
    Sciarra A
    Eur Urol; 2007 Jun; 51(6):1485-7. PubMed ID: 17275984
    [No Abstract]   [Full Text] [Related]  

  • 18. Centrally acting mechanisms for the treatment of male sexual dysfunction.
    Miner MM; Seftel AD
    Urol Clin North Am; 2007 Nov; 34(4):483-96, v. PubMed ID: 17983889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common approach to managing lower urinary tract symptoms and erectile dysfunction.
    Taylor JM; Desouza R; Wang R
    Asian J Androl; 2008 Jan; 10(1):45-53. PubMed ID: 18087643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.